Protagonist Logo. Click to navigate to a home page

2023 Annual Congress of the European Hematology Association

June 8-11, 2023

Frankfurt, Germany


Title: Rusfertide (PTG-300) improves polycythemia vera (PV) related symptoms in PV patients

Abstract Code: P1016

Presenting Author: Andrew Kuykendall , M.D., Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center

Session Date and Time: Friday, June 9, 18:00 - 19:00 CEST


Title: Pharmacokinetic and pharmacodynamic effects of rusfertide in polycythemia vera: Results from an ongoing Phase 2 study in patients with elevated hematocrit values

Abstract Code: P1048
Presenting Author: Marina Kremyanskaya , M.D., Ph.D., Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Session Date and Time: Friday, June 9 , 18:00 - 19:00 CEST


Full abstract information can be found on the EHA 2023 Hybrid Congress website at https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/.

VIEW PRESENTATION
Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.